| TA124 |
Lung cancer (non-small-cell) - pemetrexed (TA124) |
|
-
-
Pemetrexed for the treatment of non-small-cell lung cancer
Pemetrexed has now been recommended for the first-line treatment of non-small-cell lung cancer (see www.nice.org.uk/TA181). Technology appraisal guidance 124 applies to patients who have had prior chemotherapy.
- Pemetrexed is not recommended for the treatment of locally advanced or metastatic non-small-cell lung cancer.
- People currently receiving pemetrexed should have the option to continue therapy until they and their clinicians consider it appropriate to stop.
-
Other information
How this guidance was produced
Background information
This page was last updated: 04 July 2011
-
Guidance formats
-
Implementation tools and resources
See this guidance in practice
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.
